MTX-474

BIOLOGICAL3 trials

Sponsors

Mediar Therapeutics Inc., Mediar Therapeutics

Conditions

Diffuse Cutaneous Systemic SclerosisDiffuse Cutaneous Systemic Sclerosis (dcSSc)Healthy

Phase 1

A First-in-Human Safety Trial of MTX-474

CompletedNCT06535841

Mediar TherapeuticsHealthy

Start: 2024-07-10End: 2025-04-24Updated: 2025-05-18

Phase 2

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

RecruitingNCT07287670

Mediar TherapeuticsDiffuse Cutaneous Systemic Sclerosis

Start: 2026-04-16End: 2028-12-01Target: 85Updated: 2026-06-04

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Not yet recruitingCTIS2025-523288-39-00

Mediar Therapeutics Inc.Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Target: 3Updated: 2026-06-29